Recently, the phase-three-study BEACON CRC showed that patients with BRAF V600E mutated mCRC benefit from the doublet or triplet chemotherapy-free targeted combination therapy of encorafenib (a BRAF inhibitor), and cetuximab (an anti-EGFR antibody) or the latter ones combined with binimetinib (a MEK inhibitor) in a second or third line setting [30] (http://clinicaltrials.gov/show/NCT02928224). The gene discussed is BRAF; the disease is colorectal carcinoma.